Bausch + Lomb (NYSE:BLCO) vs. Kewaunee Scientific (NASDAQ:KEQU) Head to Head Review

Kewaunee Scientific (NASDAQ:KEQU) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Kewaunee Scientific and Bausch + Lomb, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0	1	0	0	2.00
Bausch + Lomb	1	8	4	1	2.36

Bausch + Lomb has a consensus target price of $20.83, indicating a potential upside of 3.78%. Given Bausch + Lomb’s stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Kewaunee Scientific.

Volatility & Risk

Kewaunee Scientific has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Profitability

This table compares Kewaunee Scientific and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	2.97%	11.61%	4.82%
Bausch + Lomb	-2.05%	5.02%	2.34%

Earnings & Valuation

This table compares Kewaunee Scientific and Bausch + Lomb”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$277.21 million	0.35	$9.62 million	$2.76	12.10
Bausch + Lomb	$5.42 billion	1.32	-$360.00 million	($0.31)	-64.76

Kewaunee Scientific has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.7% of Kewaunee Scientific shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 14.1% of Kewaunee Scientific shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kewaunee Scientific beats Bausch + Lomb on 9 of the 15 factors compared between the two stocks.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.